Cadherin 1 (CDH1)

Overview

CDH1 encodes E-cadherin, a calcium-dependent cell adhesion protein that is a central component of adherens junctions in epithelial tissues. By mediating cell–cell adhesion, CDH1 helps maintain epithelial integrity, polarity, and barrier function. Loss or reduction of CDH1 expression is widely associated with epithelial-mesenchymal transition (EMT), increased motility, and invasive behavior in cancer, and it is also clinically important in hereditary cancer predisposition, particularly in CDH1-mutated patients undergoing prophylactic or therapeutic gastric surgery.

In biomedical research, CDH1 is frequently used as an epithelial marker and readout of EMT status. Changes in CDH1 expression are often interpreted alongside mesenchymal markers such as vimentin and N-cadherin, and with EMT-associated transcription factors including Snail, Slug, Zeb1, Twist, and ZEB2. In the recent studies summarized below, CDH1/E-cadherin was used primarily as a marker of epithelial differentiation, barrier integrity, and treatment response in cancer, kidney injury, and other disease models.

Recent Publications Summary

Recent studies examined Cadherin 1 (CDH1) across several cancer contexts, most prominently as a marker and functional regulator of epithelial integrity, invasion, and treatment response. In head and neck squamous cell carcinoma, CDH1 was analyzed alongside CDH2 and CDH3 using RT-qPCR, TCGA-based multi-omics, survival analyses, miRNA-mRNA prediction, immune association tools, and siRNA knockdown in FaDu and SCC9 cells. CDH1 was significantly upregulated in HNSC cell lines and tumor samples, and functional assays were used to test its contribution to proliferation, colony formation, migration, and xenograft growth 42421103Jul. In urothelial bladder cancer, CDH1 was investigated as a prognostic gene through analysis of polymorphisms and haplotypes, reflecting interest in how genetic variation in the E-cadherin-encoding gene may relate to disease outcome 42334742Jun.

CDH1 loss was also central to studies of invasive lobular carcinoma, where the absence of E-cadherin was linked to dependence on a collagen-rich extracellular matrix. In this setting, genome-wide CRISPR-Cas screening identified ITGAV and ITGB5 as synthetic lethal partners of CDH1, and inhibition of lysyl oxidase with PXS-5505 remodeled collagen, suppressed tumor expansion and metastatic seeding, and downregulated MYC, NF-κB, and AP-1-associated transcriptional programs 41706704Feb. These findings support a model in which CDH1-deficient tumors can be vulnerable to interventions that disrupt collagen-integrin signaling.

CDH1 was also incorporated into clinical surgical research in gastric cancer, where minimally invasive total gastrectomy was performed for both gastric cancer and prophylaxis in CDH1-mutated patients. In this retrospective cohort, robot-assisted surgery was associated with fewer 30-day postoperative complications than laparoscopic surgery, while the study also tracked anastomotic leak, blood loss, severe complications, lymph node yield, and 90-day mortality 42156604May. Together, these publications portray CDH1 as both a biomarker of epithelial state and a biologically actionable determinant of tumor behavior, with implications for prognosis, surgical management, and targeted therapeutic strategies.

What Changes, What Holds

1. CDH1 now appears to have context-dependent oncogenic as well as epithelial-marker behavior
NEW DIRECTION Head and neck and bladder cancer work broadens CDH1 beyond the Overview’s mainly epithelial-integrity and EMT-readout role. In HNSC, the gene is reported as upregulated and functionally linked to proliferation, migration, and xenograft growth, which sits awkwardly with the usual view of CDH1 loss as the cancer-associated event 42421103Jul. That does not overturn the baseline, but it does suggest CDH1 may be informative in some tumors as more than a simple marker of epithelial state.

2. CDH1-deficient tumors may be therapeutically vulnerable to matrix and integrin disruption
NEW DIRECTION Loss of E-cadherin is still consistent with the Overview’s cancer-invasion framework, but this work adds a more specific dependency: CDH1-deficient invasive lobular carcinoma may rely on collagen-rich extracellular matrix signaling and integrin partners. That shifts CDH1 from being only a marker of EMT-like behavior to a determinant of actionable matrix dependence, with synthetic-lethal and collagen-remodeling strategies emerging from the CDH1-null state 41706704Feb. The evidence is preclinical, so clinical generalization remains unsettled.

3. CDH1-mutated gastric surgery is being refined, not redefined
REINFORCES Surgical use in CDH1-mutated gastric cancer fits the baseline’s statement that CDH1 status is clinically important in hereditary cancer predisposition and gastric surgery. The new comparison of minimally invasive approaches does not change what CDH1 means biologically; it sharpens perioperative management questions for patients already known to need prophylactic or therapeutic gastrectomy 42156604May. The main implication is procedural rather than mechanistic: CDH1 remains a stratifier for surgical decision-making, not a new disease pathway.

Overview update candidates: CDH1-dependent matrix/integrin vulnerability in invasive lobular carcinoma; context-dependent oncogenic associations in HNSC and bladder cancer are not yet established enough for the Overview.